Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes

What happened

Vanda Pharmaceuticals reported positive Phase 3 trial results for Nereus, an oral therapy to prevent vomiting from GLP-1 treatments. Patients had a 27% relative reduction in vomiting, with 43% of treated patients vomiting versus 58.5% on placebo.

Confirmed

Global impact / market context

Vomiting is a key reason patients stop GLP-1 drugs, a market exceeding $50 billion. If Nereus is approved for this use, Vanda could earn revenue from a new label while helping patients stay on treatment longer.

Analyst inference

Vanda stock trades at depressed levels, so positive trial news may draw investor attention. The company still needs regulator discussions and a supplemental application, which means approval and any revenue are uncertain and likely months away.

Analyst inference

What to watch

1. Vanda plans to discuss combined Phase 2 and Phase 3 data with the U.S. Food and Drug Administration before submitting a supplemental New Drug Application to expand the Nereus label. Confirmed
2. Vanda intends to file a supplemental New Drug Application seeking approval to market Nereus, known generically as tradipitant, for preventing vomiting in patients receiving GLP-1 treatments. Proposed
3. Watch whether regulators accept the trial data for a label expansion, since approval would let Vanda sell Nereus into the large GLP-1 market and potentially lift its depressed stock. Analyst inference

Evidence

• Original source link unavailable